Do Arbutus Biopharma Corporation (ABUS) beta value of 2.66 signposts another twist? – Invest Chronicle
Home  »  Industry   »  Do Arbutus Biopharma Corporation (ABUS) beta value...

Do Arbutus Biopharma Corporation (ABUS) beta value of 2.66 signposts another twist?

For the readers interested in the stock health of Arbutus Biopharma Corporation (ABUS). It is currently valued at $2.38. When the transactions were called off in the previous session, Stock hit the highs of $2.43, after setting-off with the price of $2.31. Company’s stock value dipped to $2.275 during the trading on the day. When the trading was stopped its value was $2.34.Recently in News on May 17, 2022, Arbutus to Present at H.C. Wainwright Global Investment Conference. Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 11:30 am ET in Miami, FL. You can read further details here

Arbutus Biopharma Corporation had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.01 on 01/03/22, with the lowest value was $1.93 for the same time period, recorded on 05/10/22.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Arbutus Biopharma Corporation (ABUS) full year performance was -15.83%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Arbutus Biopharma Corporation shares are logging -63.31% during the 52-week period from high price, and 23.58% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.93 and $6.50.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 726491 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Arbutus Biopharma Corporation (ABUS) recorded performance in the market was -39.85%, having the revenues showcasing -22.52% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 310.38M, as it employees total of 85 workers.

The Analysts eye on Arbutus Biopharma Corporation (ABUS)

According to the data provided on, the moving average of the company in the 100-day period was set at 2.90, with a change in the price was noted -1.42. In a similar fashion, Arbutus Biopharma Corporation posted a movement of -37.17% for the period of last 100 days, recording 2,156,710 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ABUS is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical rundown of Arbutus Biopharma Corporation (ABUS)

Raw Stochastic average of Arbutus Biopharma Corporation in the period of last 50 days is set at 36.43%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 62.67%. In the last 20 days, the company’s Stochastic %K was 56.00% and its Stochastic %D was recorded 55.05%.

Considering, the past performance of Arbutus Biopharma Corporation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -39.85%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -28.88%, alongside a downfall of -15.83% for the period of the last 12 months. The shares increased approximately by 13.59% in the 7-day charts and went up by -9.65% in the period of the last 30 days. Common stock shares were lifted by -22.52% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts